David Braley Chair in Human Stem Cell Research
Assistant Professor, Department of Biochemistry and Biomedical Sciences
Location: MDCL 5030
“My scientific goals are fueled by the desire to find long-term solutions to the daily struggles of individuals living with neurological disorders.”
The overall goal of Dr. Karun Singh’s research program is to use stem cell-based models to study neurological disorders and devise new therapies for these conditions. Currently, his program is focused on studying autism and neuropathy.
Dr. Singh joined the SCC-RI for its unique commitment to working with human cells and its established proficiency in using stem cells to generate the tissue types needed to study human disease. This is especially valuable to the Singh program as it requires human neural cells for study, which are not easily accessed in patients. With his ability to generate the human neurons needed to study these conditions in vitro, Dr. Singh is making strides in furthering what is known about these severely understudied conditions.
In addition to shedding new light on the molecular mechanisms underlying these conditions, Dr. Singh’s lab is working extensively in the realm of drug discovery through the use of the SCC-RI’s drug discovery screening platform. He has adapted the platform to develop new drug screens for these neural conditions.
The ability to screen for drugs that can target the root causes of neural disorders, including pain and dysfunction in autism spectrum disorder.
To develop the first Canadian high-throughput drug screening platform using autism spectrum disorder patient-derived neurons to ultimately move drugs to clinical trial testing.
Screening for repurposed drugs that rescue our preclinical TAO2 autism spectrum disorder models, and working to move these into Phase I clinical trials.
Neuron. 2010 Jul 15;67(1):33-48.
Cell Reports. 2016 Nov 8; 17(7): 1892-1904.
Single Transcription Factor Conversion of Human Blood Fate to NPCs with CNS and PNS Developmental Capacity.
Cell Reports. 2015 Jun 9;11(9):1367-76.